Objetivo Health and wellbeing are among the basic and most essential needs of humanity. Medicines have a major impact on the quality of life and are essential for treating various diseases. Despite the major achievements of the pharmaceutical industry, there are still diseases without effective treatment, such as different types of cancers and neurodegenerative diseases, including Alzheimer’s disease. Pharmaceutical industry is continuously searching for new compounds that can become drug candidates against such diseases. The first key stage of early-phase drug discovery is to select the most appropriate candidate molecules. However, researchers can typically select and order the starting compounds only from the 7-8 million molecules available “off-the-shelf” from suppliers. Our company, Mcule.com Ltd aims to provide the best web-based drug discovery platform for pharmaceutical researchers (big companies, contract research organisations and academics). Our solution, the Ultimate database will not only integrate all purchasable “off-the-shelf” compounds from multiple suppliers, but also includes virtual compounds, which are not yet synthesized, but predicted to be synthesizable with low effort for a reasonable price (https://mcule.com/ultimate-project/). To demonstrate the concept, in 2016 Mcule integrated the first set of virtual compounds and became the largest chemical web shop of the world offering 35 million purchasable compounds. In this project, we aim to create an easily searchable chemical database of 500 million purchasable compounds. Such a large chemical space would present a major advantage for pharmaceutical and biotech companies by increasing their chances to effectively identify novel compounds for diseases, reducing their costs and time losses. The ULTIMATE database will promote our growth by providing access to the database and web-based searching tools for a subscription fee and by increasing considerably our market share as a compound sourcing solution. Ámbito científico medical and health sciencesbasic medicinepharmacology and pharmacydrug discoverymedical and health sciencesbasic medicineneurologydementiaalzheimernatural sciencescomputer and information sciencesdatabasesmedical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsmedical and health sciencesclinical medicineoncology Palabras clave Drug discovery cheminformatics computational chemistry Programa(s) H2020-EU.2.1.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Information and Communication Technologies (ICT) Main Programme H2020-EU.2.3.1. - Mainstreaming SME support, especially through a dedicated instrument Tema(s) SMEInst-01-2016-2017 - Open Disruptive Innovation Scheme Convocatoria de propuestas H2020-SMEInst-2016-2017 Consulte otros proyectos de esta convocatoria Convocatoria de subcontratación H2020-SMEINST-2-2016-2017 Régimen de financiación SME-2 - SME instrument phase 2 Coordinador MCULE.COM KFT Aportación neta de la UEn € 1 408 163,00 Dirección BARTOK BELA UT 105-113 1115 Budapest Hungría Ver en el mapa Pyme Organización definida por ella misma como pequeña y mediana empresa (pyme) en el momento de la firma del acuerdo de subvención. Sí Región Közép-Magyarország Budapest Budapest Tipo de actividad Private for-profit entities (excluding Higher or Secondary Education Establishments) Enlaces Contactar con la organización Opens in new window Participación en los programas de I+D de la UE Opens in new window Red de colaboración de HORIZON Opens in new window Coste total € 2 011 662,50
